These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17433631)

  • 1. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.
    Fish DN
    Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients.
    Kanji S; McKinnon PS; Barletta JF; Kruse JA; Devlin JW
    Crit Care Med; 2003 May; 31(5):1347-52. PubMed ID: 12771601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
    van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
    J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.
    Rebuck JA; Fish DN; Abraham E
    Pharmacotherapy; 2002 Oct; 22(10):1216-25. PubMed ID: 12389872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gatifloxacin pharmacokinetics in healthy men and women.
    Zhang X; Overholser BR; Kays MB; Sowinski KM
    J Clin Pharmacol; 2006 Oct; 46(10):1154-62. PubMed ID: 16988204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case-controlled analysis.
    Mohr JF; Peymann PJ; Troxell E; Lodise TP; Ostrosky-Zeichner L
    Clin Ther; 2008 Jan; 30(1):152-7. PubMed ID: 18343251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of gatifloxacin in broiler chickens following intravenous and oral administration.
    Devada SS; Patel SD; Patel HB; Patel NN; Bhavsar SK; Thaker AM
    Br Poult Sci; 2012; 53(2):257-61. PubMed ID: 22646791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
    Bhalodi AA; Keel RA; Quintiliani R; Lodise TP; Nicolau DP; Kuti JL
    Ann Pharmacother; 2013 May; 47(5):617-27. PubMed ID: 23585647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
    Ambrose PG; Forrest A; Craig WA; Rubino CM; Bhavnani SM; Drusano GL; Heine HS
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4351-5. PubMed ID: 17875992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage.
    Kikuchi J; Yamazaki K; Kikuchi E; Ishizaka A; Nishimura M
    Clin Ther; 2007 Jan; 29(1):123-30. PubMed ID: 17379052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
    Conte JE; Golden JA; McIver M; Zurlinden E
    Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
    Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development.
    Rubino CM; Ambrose P; Cirincione B; Arguedas A; Sher L; Lopez E; Sáez-Llorens X; Grasela DM
    Diagn Microbiol Infect Dis; 2007 Sep; 59(1):67-74. PubMed ID: 17875453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
    Pea F; Di Qual E; Cusenza A; Brollo L; Baldassarre M; Furlanut M
    Clin Pharmacokinet; 2003; 42(6):589-98. PubMed ID: 12793843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg.
    Szałek E; Tomczak H; Kamińska A; Grabowski T; Smuszkiewicz P; Matysiak K; Wolc A; Kaczmarek Z; Grześkowiak E
    Adv Med Sci; 2012; 57(2):217-23. PubMed ID: 22968336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.
    Myrianthefs P; Markantonis SL; Vlachos K; Anagnostaki M; Boutzouka E; Panidis D; Baltopoulos G
    Antimicrob Agents Chemother; 2006 Dec; 50(12):3971-6. PubMed ID: 16982782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.